by Francisca Peixoto | May 12, 2026 | Uncategorized
Our portfolio company, Immunitas Therapeutics, has announced a $478 Million global licensing agreement of their preclinical antibody program to advance treatments for chronic inflammatory diseases with Boehringer Ingelheim. The program is designed to selectively...
by Francisca Peixoto | Apr 16, 2026 | Uncategorized
Our portfolio company, Spiral Therapeutics, has raised a $27 million Series B financing round to advance a pipeline of programs targeting diseases of the inner ear. Despite representing a significant area of unmet medical need, the inner ear remains one of the least...
by Francisca Peixoto | Apr 7, 2026 | Uncategorized
Our portfolio company, AIRNA, has begun dosing participants in a Phase 1 clinical trial of AIR-001, Potential Best-in-Class RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD). AIRNA has begun dosing participants in a Phase 1 clinical trial of AIR-001....
by Francisca Peixoto | Mar 18, 2026 | Uncategorized
We are excited to announce another exciting addition to LifeLink’s portfolio, Crossbow Therapeutics. We’re very proud to have joined the $77 million Series B financing round, led by Taiho Oncology and Arkin Capital, with participation from Eli Lilly and...
by Francisca Peixoto | Feb 16, 2026 | Uncategorized
Alba holds a MSc in Oncology from University College London and a biochemistry BSc degree from the Technical University of Munich. Her academic training provided her with a strong foundation in molecular and biochemical processes, which she further specialized in the...
by Francisca Peixoto | Jul 23, 2025 | Uncategorized
Our portfolio company, Eveliqure Biotechnologies, has begun dosing participants in a Phase 2b clinical trial of its oral ShigETEC vaccine. Eveliqure Biotechnologies has begun dosing participants in a Phase 2b clinical trial of its oral ShigETEC vaccine, designed to...
